Law360, New York (January 19, 2011, 3:36 PM EST) -- A federal judge Wednesday found the patent for Novo Nordisk A/S diabetes drug Prandin invalid because of obviousness and unenforceable due to inequitable conduct, paving the way for Caraco Pharmaceutical Laboratories Ltd. to market a generic version.
The decision by Judge Avern Cohn of the U.S. District Court for the Eastern District of Michigan comes after a six-year legal battle over whether the patent could be sustained.
The judge ruled that the idea covered by the patent to combine repaglinide with metformin as a combination therapy...
Judge Finds Novo's Prandin Patent Invalid
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
